Understanding Immuno-Oncology Development and Opportunities

Sponsored by: GlobalData

Focused on:

  • Immuno Oncology
  • I O
  • Data Insights

Date: 13 October


Time: 3PM London/10AM New York

Data-Driven Analysis of the Immuno-Oncology (IO) Development to Generate Unique Actionable Insights

Immuno-Oncology (IO) looks set to become the fifth pillar of cancer treatment alongside surgery, radiotherapy, chemotherapy, and other targeted treatments. Despite the high interest in the IO field, it has become an increasing challenge to monitor this area due to a highly dynamic clinical and market landscape.

Benefiting from the GlobalData’s unique core of expertise, the company’s health team analyzed over 4,000 clinical trials and more than 800 IO products in Phase I–III development to generate a number of actionable insights. GlobalData’s analysis predominantly focuses on developments in active immunotherapy products based on their molecular targets and molecule types. IO product categories covered in the report include immune checkpoint modulators (based on 21 individual targets), cellular immunotherapies (including CAR T-cell therapies), cancer vaccines, oncolytic viruses, and bispecific T-cell engagers. The report also covers a total of 18 solid tumor types and eight blood cancers.

Of the big advances in cancer care over recent years, excitement around the clinical and market potential of IO has been driven by IO’s ability to improve patient survival. The future of IO looks brighter than ever, and IO drugs are now in a position to compete as monotherapies against traditional SOC chemotherapy regimens in the first line of the metastatic setting. In addition, these treatments have shown efficacy in a wide variety of indications offering a less toxic treatment alternative.

In this webinar, GlobalData’s Senior Analyst covering Oncology, Dr. Maxime Bourgognon, will share insights pulled from GlobalData’s PharmaFocus: Visual Analysis of Immuno-Oncology Development and Opportunities. Dr. Bourgognon will present GlobalData’s methodology to analyze the IO landscape, and share analysis about key IO therapies such as immune checkpoint modulators and CAR T-cells therapies. Dr. Fern Barkalow, GlobalData’s Director covering Oncology, will moderate a Q&A session following the presentation.

Join this webinar to increase your knowledge of the current state of the IO market and understand how GlobalData can help monitoring the current state of the IO development.

Presented by

Maxime Bourgognon,

Senior Analyst in Oncology and Hematology

Maxime Bourgognon, PhD, PharmD, is an Oncology and Hematology Senior Analyst for GlobalData, where he provides strategic and market insights in the form of syndicated reports and consulting projects to pharma and healthcare clients. Before joining GlobalData, Max worked at the Institute of Pharmaceutical Science at King’s College London as a Research Assistant and PhD student. His research was based on designing and testing novel nanomedicines for targeting and treating cancer. Prior to this, he completed a PharmD at the Faculty of Pharmaceutical Sciences in Toulouse, France.

Maxime obtained his MSc in Pharmaceutical Biotechnology at the Faculty of Pharmaceutical Sciences of Montpellier in France, and attained pre-clinical research experience during an industrial internship at the Centre of Immunology of Pierre Fabre Laboratories. While obtaining his undergraduate degree, he was also involved in academic research projects at the Claudius Regaud Institute in Toulouse, France, and the Cambridge Research Institute in the UK.

Fern Barkalow,

Director of Oncology and Hematology

Fern Barkalow, PhD, has nearly 20 years of experience in the biopharmaceutical industry, as well as a research background in the molecular mechanisms of inflammation and metastasis. After leaving the lab bench, Fern moved into the database group at Incyte Pharmaceuticals, where she helped develop the Proteome BioKnowledge Library, and led a cross-functional team tasked with creating databases covering diseases and molecular interactions. She then joined the Medical Affairs group at Millennium Pharmaceuticals and managed medical writing projects involving clinical trials results for oncology drugs.

Most recently, Fern was Associate Director of the Oncology team at Citeline, where she participated in developing and managing the Trialtrove database and interacted with clients through the research support service and custom analytics projects. Fern holds a PhD in Microbiology from The University of Medicine and Dentistry of New Jersey, and was a postdoctoral fellow in Molecular Biology at Princeton University and in Pathology at Brigham and Women’s Hospital in Boston.

Key Learning Objectives

  • Understand how the GlobalData’s Pharma Intelligence Center database supports the analysis of the IO landscape.
  • Gain insight on the most promising classes of IO products such as immune checkpoint modulators and CAR T-cell therapies.
  • Identify key clinical development and market opportunities across the IO field.
  • See how the highly-visual IO report can facilitate the dissemination of aggregated data and insights throughout your organization.


  • Managers/Senior Managers/Associate Directors/Directors of Market Research
  • Business Insights
  • Market Intelligence
  • Strategic Insights
  • Forecasting
  • Pipeline Management
  • Competitive Strategy
  • Customer Insights
  • Heads of Research and Development
  • Heads of Product Planning and Marketing
  • Brand Managers